Cardiac resynchronization therapy in women: US food and drug administration meta-analysis of patient-level data

JAMA Internal Medicine

Volumn 174, Issue 8, 2014, Pages 1340-1348

  Zusterzeel, Robbert ^a   Selzman, Kimberly A ^a   Sanders, William E ^a   Canos, Daniel A ^a   O'Callaghan, Kathryn M ^a   Carpenter, Jamie L ^a   Pina, Ileana L ^a   Strauss, David G ^a  

^a CENTER FOR DEVICES AND RADIOLOGICAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; BUNDLE-BRANCH BLOCK; CARDIAC RESYNCHRONIZATION THERAPY; CARDIAC RESYNCHRONIZATION THERAPY DEVICE; COMPARATIVE STUDY; FEMALE; FOOD AND DRUG ADMINISTRATION; HEART FAILURE; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; META ANALYSIS; MIDDLE AGED; MORTALITY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; UNITED STATES;

AGED; BUNDLE-BRANCH BLOCK; CARDIAC RESYNCHRONIZATION THERAPY; CARDIAC RESYNCHRONIZATION THERAPY DEVICES; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HEART FAILURE; HUMANS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84905851582     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.2717     Document Type: Article

References (38)

1. US Food and Drug Administration. Availability of masked and de-identified non-summary safety and efficacy data; request for comments. http://www .gpo.gov/fdsys/pkg/FR-2013-06-04/html/2013-13083.htm. Accessed July 7, 2013.
2. US Food and Drug Administration. Food and Drug Administration Safety and Innovation Act (FDASIA). http://www.fda.gov/RegulatoryInformation/Legislation/ FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDASIA/. Accessed May 7, 2014.
3. Moss AJ, HallWJ, Cannom DS, et al; MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361(14): 1329-1338.
4. Tang AS,Wells GA, Talajic M, et al; Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiacresynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363(25): 2385-2395.
5. Linde C, AbrahamWT, GoldMR, St John Sutton M, Ghio S, Daubert C; REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) Study Group. Randomized trial of cardiac resynchronization inmildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J AmColl Cardiol. 2008;52(23): 1834-1843.
6. BristowMR, Saxon LA, Boehmer J, et al; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004; 350(21): 2140-2150.
7. Cleland JG, Daubert JC, Erdmann E, et al; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl JMed. 2005;352(15): 1539-1549.
8. Mooyaart EA, Marsan NA, van Bommel RJ, et al. Comparison of long-term survival of men versus women with heart failure treated with cardiac resynchronization therapy. Am J Cardiol. 2011;108 (1): 63-68.
9. Xu YZ, Friedman PA,Webster T, et al. Cardiac resynchronization therapy: do women benefit more than men? J Cardiovasc Electrophysiol. 2012;23(2): 172-178.
10. Arshad A, Moss AJ, Foster E, et al; MADIT-CRT Executive Committee. Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. J AmColl Cardiol. 2011;57(7): 813-820.
11. Cheng A, GoldMR,Waggoner AD, et al. Potential mechanisms underlying the effect of gender on response to cardiac resynchronization therapy: insights from the SMART-AV multicenter trial. Heart Rhythm. 2012;9(5): 736-741.
12. Dhruva SS, Bero LA, Redberg RF. Gender bias in studies for Food and Drug Administration premarket approval of cardiovascular devices. Circ Cardiovasc Qual Outcomes. 2011;4(2): 165-171.
13. Sipahi I, Chou JC, Hyden M, Rowland DY, Simon DI, Fang JC. Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Am Heart J. 2012;163(2): 260-267.
14. Sipahi I, Carrigan TP, Rowland DY, Stambler BS, Fang JC. Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Arch Intern Med. 2011;171(16): 1454-1462.
15. Tracy CM, Epstein AE, Darbar D, et al. 2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Heart Rhythm. 2012;9(10): 1737-1753.
16. Macfarlane P, Van Oosterom A, Pahlm O, Kligfield P, Janse MJ, Camm J. Appendix 1: adult normal limits. In: Macfarlane P, Van Oosterom A, Pahlm O, Kligfield P, Janse MJ, Camm J, eds. Comprehensive Electrocardiology. Vol 4. 2nd ed. London, England: Springer-Verlag; 2011: 2057-2126.
17. Mascioli G, Padeletti L, Sassone B, et al. Electrocardiographic criteria of true left bundle branch block: a simple sign to predict a better clinical and instrumental response to CRT. Pacing Clin Electrophysiol. 2012;35(8): 927-934.
18. Strauss DG, Selvester RH,Wagner GS. Defining left bundle branch block in the era of cardiac resynchronization therapy. Am J Cardiol. 2011;107 (6): 927-934.
19. US Food and Drug Administration. Circulatory systems devices panel transcript for MADIT-CRT. 2010; http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/ CirculatorySystemDevicesPanel/UCM215463.doc. Accessed April 4, 2013.
20. US Food and Drug Administration. Circulatory systems devices panel transcript for RAFT/REVERSE. 2011; http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/ MedicalDevicesAdvisoryCommittee/CirculatorySystemDevicesPanel/UCM289085.pdf. Accessed April 4, 2013.
21. GoldMR, Thébault C, Linde C, et al. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes inmild heart failure: results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study. Circulation. 2012;126 (7): 822-829.
22. Loring Z, Canos DA, Selzman K, et al. Left bundle branch block predicts better survival in women than men receiving cardiac resynchronization therapy: long-term follow-up of 145,000 patients. JACC Heart Fail. 2013;1(3): 237-244.
23. ZarebaW, Klein H, Cygankiewicz I, et al; MADIT-CRT Investigators. Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation. 2011;123(10): 1061-1072.
24. Cleland JG, AbrahamWT, Linde C, et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013;34(46): 3547-3556.
25. Bilchick KC, Kamath S, DiMarco JP, Stukenborg GJ. Bundle-branch block morphology and other predictors of outcome after cardiac resynchronization therapy in Medicare patients. Circulation. 2010;122(20): 2022-2030.
26. Peterson PN, Greiner MA, Qualls LG, et al. QRS duration, bundle-branch block morphology, and outcomes among older patients with heart failure receiving cardiac resynchronization therapy. JAMA. 2013;310(6): 617-626.
27. Tian Y, Zhang P, Li X, et al. True complete left bundle branch block morphology strongly predicts good response to cardiac resynchronization therapy. Europace. 2013;15(10): 1499-1506.
28. Goldenberg I, Moss AJ, HallWJ, et al; MADIT-CRT Executive Committee. Predictors of response to cardiac resynchronization therapy in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT). Circulation. 2011;124(14): 1527-1536.
29. Strauss DG, Loring Z, Selvester RH, et al. Right, but not left, bundle branch block is associated with large anteroseptal scar. J Am Coll Cardiol. 2013;62 (11): 959-967.
30. Dhruva SS, Redberg RF. Evaluating sex differences in medical device clinical trials: time for action. JAMA. 2012;307(11): 1145-1146.
31. US Food and Drug Administration. Draft guidance for industry and Food and Drug Administration staff: evaluation of sex differences in medical device clinical studies. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/ GuidanceDocuments/ucm283453.htm. Accessed March 6, 2013.
32. Code of Federal Regulations. Title 21, Section 20.61. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=20.61. Accessed May 8, 2014.
33. Code of Federal Regulations. Title 21, Section 814.9. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=814.9. Accessed May 8, 2014.
34. Liu J, Florian J, Birnkrant D, Murray J, Jadhav PR. Interferon responsiveness does not change in treatment-experienced hepatitis C subjects: implications for drug development and clinical decisions. Clin Infect Dis. 2012;55(5): 639-644.
35. Soon GG, MinM, Struble KA, et al. Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000-2008). AIDS Patient Care STDS. 2012;26(8): 444-453.
36. Nisen P, Rockhold F. Access to patient-level data from GlaxoSmithKline clinical trials. N Engl J Med. 2013;369(5): 475-478.
37. Krumholz HM, Ross JS, Gross CP, et al. A historic moment for open science: the Yale University Open Data Access Project and Medtronic. Ann Intern Med. 2013;158(12): 910-911.
38. Steinbrook R. The European Medicines Agency and the brave new world of access to clinical trial data. JAMA Intern Med. 2013;173(5): 373-374.